The value of permixon in benign prostatic hypertrophy
- PMID: 2418902
- DOI: 10.1111/j.1464-410x.1986.tb05424.x
The value of permixon in benign prostatic hypertrophy
Abstract
A double-blind trial comparing the effect of Permixon (160 mg bd) against placebo in the treatment of benign prostatic hypertrophy is described. In both groups a significant improvement in flow rate and subjective assessment of symptoms was seen. There was no significant difference between the results of treatment in either group.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical